Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment with a GnRh agonists Clear all
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 28, 2026, 4:37 PM EDT
Terminated Phase 2 Interventional Results available

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions
Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
50 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 28, 2026, 4:37 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

NCT01603420
View directory record Official record
Conditions
Prostate Cancer
Interventions
Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
Drug · Other
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years to 75 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Warrenville, Illinois • Oklahoma City, Oklahoma • Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 28, 2026, 4:37 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Adaptions and Resiliency to Multi-Stressor OpeRations

NCT06455969
View directory record Official record
Conditions
Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
Interventions
Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g)
Drug · Other
Lead sponsor
Bradley Nindl
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 4:37 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 28, 2026, 4:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer

NCT03275181
View directory record Official record
Conditions
Prostate Cancer
Interventions
Transthoracic Echocardiography, Arterial blood pressure, Submaximal Exercise
Diagnostic Test
Lead sponsor
Kansas State University
Other
Eligibility
21 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 28, 2026, 4:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
4,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
72
States / cities
Daphne, Alabama • Bakersfield, California • Fullerton, California + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 28, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 28, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

NCT01360840
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
EMD 525797, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Pleasant Hill, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 28, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 28, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

NCT01546987
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH agonist, Anti-androgen, TAK-700, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 28, 2026, 4:37 PM EDT
Active, not recruiting Phase 2 Interventional

INTREPId (INTermediate Risk Erection PreservatIon Trial)

NCT04025372
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Drug · Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Stamford, Connecticut • Boston, Massachusetts • Milford, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 28, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

NCT00329797
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D
Dietary Supplement · Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
80
States / cities
Chico, California • Los Angeles, California • Pomona, California + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 28, 2026, 4:37 PM EDT
Terminated No phase listed Observational

The Relation of GnRH Treatment to QTc Interval in Transgender Females

NCT03078829
View directory record Official record
Conditions
Gender Dysphoria
Interventions
Treatment with a GnRh agonists
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 28, 2026, 4:37 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

NCT07313241
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 4:37 PM EDT
Terminated Phase 3 Interventional Results available

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

NCT03777982
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 4:37 PM EDT